El interés en corto de aTyr Pharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de aTyr Pharma. Los datos de interés en corto se actualizan cada dos semanas.

aTyr Pharma (NASDAQ:ATYR) Bolsa, Informe de interés en corto

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

Jefferies analyst Peter Abramowitz initiates coverage on SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) with a Hold rating and announces Price Target of $58.

News

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On SL Green Realty with Hold Rating, Announces Price Target of $58

Ascendiant Capital analyst Edward Woo maintains Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) with a Buy and raises the price target from $14 to $19.

GRPN

Ascendiant Capital Maintains Buy on Groupon, Raises Price Target to $19

As of March 17, 2025, two stocks in the utilities sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 7</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Consolidated Water Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>)</h3>
<ul>
<li>On Feb. 26, Consolidated Water announced that its board of directors has approved a quarterly cash dividend of 11 cents per share for the second quarter of 2025. The company's stock gained around 6% over the past five days and has a <a href="https://www.benzinga.com/quote/CWCO">52-week high of $33.34</a>.</li>
<li>RSI Value: 71.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CWCO Price Action: Shares of Consolidated Water gained 2.8% to close at $29.18 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Centrais Eletricas Brasileiras SA &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBR#NYSE">EBR</a>)</h3>
<ul>
<li>The company's stock gained around 5% over the past five days and <a href="https://www.benzinga.com/quote/EBR">has a 52-week high</a> of $8.72.</li>
<li>RSI Value: 72.4</li>
<li>EBR Price Action: Shares of Centrais Eletricas Brasileiras gained 2.6% to close at $7.03 on Friday. </li>
</ul>
Read This Next:<a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CWCO

Top 2 Utilities Stocks That May Fall Off A Cliff In Q1

Shares of Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/DTIL">pre-market trading</a>.
Precision BioSciences reported clearance of investigational new drug application by the U.S. FDA for first-in-class PBGENE-HBV designed to eliminate root cause of chronic hepatitis B.
Precision BioSciences shares climbed 10.8% to $5.58 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) gained 42.3% to $3.11 in pre-market trading.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) rose 36.7% to $0.1532 in pre-market trading after dipping 20% on Friday.</li>
<li>SES AI Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SES#NASDAQ">SES</a>) gained 29.1% to $0.5675 in pre-market trading after gaining 9% on Friday.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) gained 27.4% to $0.9837 in pre-market after gaining 13% on Friday.</li>
<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) gained 21.3% to $1.65 in pre-market trading after jumping 19% on Friday.</li>
<li>Inuvo, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INUV#NYSE">INUV</a>) gained 18.2% to $0.45 in pre-market trading.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) gained 16.5% to $0.9076 in pre-market trading.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 15% to $8.15 after jumping 29% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) rose 11% to $1.61 in pre-market trading after jumping 14% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fold Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLD#NASDAQ">FLD</a>) shares fell 18.8% to $6.00 in pre-market trading after gaining around 8% on Friday.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 15.3% to $57.50 in pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.</li>
<li>Planet Green Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLAG#NYSE">PLAG</a>) dipped 14.4% to $1.71 in pre-market trading.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) declined 14.1% to $2.92 in pre-market trading.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Linkage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares tumbled 13.5% to $0.1537 in pre-market trading after dipping over 22% on Friday.</li>
<li>Polar Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares fell 12.3% to $2.36 in pre-market trading.</li>
<li>Aspira Women&#8217;s Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) fell 10.8% to $0.1250 in today's pre-market trading after dipping over 8% on Friday. Aspira Women&#8217;s Health recently announced closing of $1.37 million private placement of convertible notes.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44350021/science-applications-international-getty-images-and-3-stocks-to-watch-heading-into-monday">Science Applications International, Getty Images And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>

Movers

ACON

DRCT

DTIL

INCY

INUV

KULR

LGCB

NAOV

OMER

PLAG

POLA

QUBT

REVB

TYRA

USAR

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Seaport Global analyst David Joyce upgrades Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) from Neutral to Buy and maintains the price target from $96 to $96.

Upgrades

FWONK

Seaport Global Upgrades Liberty Media to Buy, Maintains Price Target to $96

As the stock market wades through volatility, gold surged above $3000 per ounce on Friday. While the traditional safe haven for investors soars amid uncertainty, this expert highlights how the yellow metal undergoes correction after sharp gains.
What Happened: Gold hit an all-time high of $3,005.08 per ounce on Friday, however, D Muthukrishnan, a certified financial planner highlighted in an X post that &#8220;Gold too corrects, like every other asset class.&#8221;
According to a dataset shared by FundsIndia, &#8220;The precious metal has experienced painful drawdowns after periods of sharp gains.&#8221;
After peaking in Jan. 1980, gold declined 56% over two years and took 9 years and 11 months to recover. Similarly, after a November 2012 peak, the gold prices slid 30% in nearly three years and took 6 years and 7 months to recover.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Gold too has a place in an investor&#39;s portfolio. But don&#39;t get carried away by recent bull run. Gold too corrects, like every other asset class. <a href="https://t.co/U513vcRsCY">pic.twitter.com/U513vcRsCY</a>
&mdash; D.Muthukrishnan (@dmuthuk) <a href="https://twitter.com/dmuthuk/status/1901493385363652719?ref_src=twsrc%5Etfw">March 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, he added that &#8220;Gold too has a place in an investor&#8217;s portfolio.&#8221;
Underscoring the reason for the upmove in gold, Aditya Sesh, the founder and managing director of Basiz Fund Services said that &#8220;Any global uncertainty will push gold prices further up due to risk aversion. The current status leads one to conclude that there is high global uncertainty. This is reflected in FX and stock market movements.&#8221;
Additionally, Adam Rossi of TotalShield highlighted PriceInGold.com&#8217;s data and explained that if the S&amp;P 500 index was priced in terms of gold rather than dollars, the index has been flat since 2006.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With gold kissing $3000/oz, now is a good time to remind ourselves that when we price the S&amp;P500 in gold rather than dollars, the index is flat since 2006. That 382% return in dollars since 2006 ain't what you think it is. <a href="https://t.co/oFdJrbCVQV">pic.twitter.com/oFdJrbCVQV</a>
&mdash; Adam Rossi (@rossiadam) <a href="https://twitter.com/rossiadam/status/1900522105210315036?ref_src=twsrc%5Etfw">March 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/03/44350479/warren-buffett-plans-to-sell-his-real-estate-brokerage-but-its-not-a-bet-against-us-home-prices-says-analyst-as-fed-expects-to-keep-rates-unchanged">Warren Buffett Plans To Sell His Real Estate Brokerage, But It&#8217;s &#8216;Not… A Bet Against US Home Prices,&#8217; Says Analyst As Fed Expects To Keep Rates Unchanged</a>
Why It Matters: Despite the contrarian point of view on the yellow metal&#8217;s price surge and how it is not safe from corrections, Michael Saylor of Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), formerly MicroStrategy, compared Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to gold in the 1970s. He said, &#8220;Bitcoin today is Gold back in the 1970s,&#8221; adding that Bitcoin could climb to $300,000 per coin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin today is Gold back in the 1970&#39;s. If you don&#39;t know what happened then, look at this chart. Bitcoin will go beyond $300,000 this cycle. <a href="https://t.co/h8E8H4jWQr">pic.twitter.com/h8E8H4jWQr</a>
&mdash; Michael Saylor&#x26a1;&#xFE0F;Founder of Strategy (Fan Account) (@SaylorBuysBTC) <a href="https://twitter.com/SaylorBuysBTC/status/1901274755849650300?ref_src=twsrc%5Etfw">March 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: At the time of the publication of this article, the gold spot was trading 0.46% higher at $2,998.27 per ounce. Whereas, the U.S. dollar was down 0.21% to the 103.497 level.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Monday. The SPY was down 0.18% to $561.82, and the QQQ also declined 0.10% to $479.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
SPY closed 2.07% higher at $562.81 and QQQ rose 2.42% to $479.66 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44350934/sp-500-price-trend-flashes-warning-signals-but-this-expert-says-start-looking-for-a-buy-signal-after-last-weeks-drawdown">S&amp;P 500 Price Trend Flashes Warning Signals But This Expert Says &#8216;Start Looking For A Buy Signal&#8217; After Last Week&#8217;s Drawdown</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Commodities

$BTC

MSTR

Safe Haven Amidst Volatility? Gold Tops $3000 As Market Corrects But It Tends To See 'Painful Drawdowns After Periods Of Sharp Gains,' Says Expert

DGHI

Digi Power X Announces Nasdaq Symbol Change From DGHI To DGXX, Effective March 18, 2025

Interim CEO and Board Chairman Robert A. Berman said, "We thank David for his contributions and wish him the best of success in his future endeavors. The Board has taken steps to begin the search for a new CEO. The Executive Committee will continue to fulfill its role during the transition to ensure the Rekor team can realize global opportunities for our products and services."

Management

REKR

Rekor Systems Says Its President And CEO David Desharnais Submitted His Resignation On March 12, 2025

Earnings

LPRO

Open Lending Postpones Q4 And 2024 Earnings Release And Conference Call

Jefferies analyst Peter Abramowitz initiates coverage on Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) with a Buy rating and announces Price Target of $13.

Jefferies Initiates Coverage On Easterly Government Props with Buy Rating, Announces Price Target of $13

Based on preliminary and unaudited financial results, full-year 2024 revenue is expected to be above $45.5 million, representing a year-over-year increase above 30% compared to 2023.&nbsp;

Rekor Systems Expects Q4 Revenue To Be Above $12.5M, Reflecting Growth Above 12% YoY (Est $12.913M)

Legal

CREX

Creative Realities Settles And Resolves Dispute With Former Stockholders Of Reflect Systems; Settlement Terminates And Releases Obligation To Pay Guaranteed Consideration In Exchange For $3M Cash Payment, $4M 30-Month Promissory Note And Issuance Of Certain Warrants To Purchase Common Stock

MoffettNathanson analyst Michael Nathanson upgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Neutral to Buy and raises the price target from $850 to $1100.

NFLX

MoffettNathanson Upgrades Netflix to Buy, Raises Price Target to $1100

AVNS

Avanos Medical Taps David Pacitti As Chief Executive Officer, Effective April 14

Rebecca Kujawa, president and chief executive officer (CEO), NextEra Energy Resources, LLC, will be retiring on May 22, 2025, as part of a planned leadership succession process.
Brian Bolster, currently executive vice president and chief financial officer (CFO) of NextEra Energy, will succeed Kujawa as president and CEO at NextEra Energy Resources.

NextEra Energy Names Mike Dunne As Executive Vice President, Finance And CFO

Contracts

Centene Subsidiary,  Meridian Health Plan of Illinois, To Continue Providing Medicare And Medicaid Services For Dually Eligible Members In Illinois

ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 8.77 percent decrease over losses of $(0.57) per share from the same period last year.

PROK

ProKidney FY 2024 GAAP EPS $(0.62) Misses $(0.57) Estimate, Ended The Fourth Quarter With $358M In Cash And Cash Equivalents And Marketable Securities, Supporting Operations Into Mid-2027

Jefferies analyst Peter Abramowitz initiates coverage on BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Buy rating and announces Price Target of $78.

Jefferies Initiates Coverage On BXP with Buy Rating, Announces Price Target of $78

IREN

IREN Secures Grid Access For Sweetwater 2 As Part Of 2.75GW AI-Optimized Data Center Expansion In West Texas

Jefferies analyst Peter Abramowitz initiates coverage on Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Hold rating and announces Price Target of $100.

Jefferies Initiates Coverage On Alexandria Real Estate with Hold Rating, Announces Price Target of $100

Biotech

Press Releases

General

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Health Care

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Comments

aTyr Pharma

Interés en corto

aTyr Pharma (NASDAQ:ATYR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL